A Specialized Program of Research Excellence for patients with cancer of the head and neck entitled """"""""The Molecular Basis of Head and Neck Biology, Treatment and Prevention"""""""" is proposed that will significantly improve treatment results and reduce morbidity and mortality associated with this devastating malignancy. These goals will be achieved through improved understanding and application of molecular biology to the detection, prevention, treatment selection and development of new therapies for patients with head and neck cancers. Our ongoing hypothesis is that increased understanding of the molecular basis for treatment will allow more precise individualized patient selection that will result in less morbid therapy and improved quality of life, in addition to the possibility of better control of metastases and earlier detection or prevention of second primary malignancies. We propose continuation of this integrated translational research program consisting of four major projects that explore 1.) more specific treatment selection for patients likely to be cured with radiation or chemotherapy;2.) new small molecule inhibitors of apoptosis-regulation to increase chemo/radiosensitivity;3.) improved survival through development of sound prevention strategies;and 4.) the role of critical small molecules and chemoradiation sequencing for optimizing treatment results. These major translational projects are complemented by ongoing highly successful Career Development and Developmental Research Programs. All SPORE studies are supported by three Core Resources with demonstrated success in our initial funding period (Administration and Translational Trials Support, Biostatistics, and Tissue and Histopathology). Emphasis is placed on continued ongoing scientific review of all programs and core resources through utilization of an established Operations Committee, Senior Advisory Council and External Review Committee comprised of expert basic and clinician scientists in the field of cancer research. Strong institutional commitment in our initial funding period has been increased significantly in this renewal application to support equipment needs, our Developmental Research Program and provide increased flexibility to pursue further investigations of novel discoveries that are made as a result of these SPORE projects and collaborations. This Head and Neck SPORE is a fully integrated component of the University of Michigan Comprehensive Cancer Center. We have incorporated extensive use of Cancer Center core facilities and clinical and laboratory resources, and we draw heavily on experienced Cancer Center leadership. Superb teams of experienced clinical / basic collaborators combined with high institutional commitment and priority, and extensive patient resources provide an outstanding research environment that will ensure continued success in achieving overall SPORE goals.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Program Officer
Ujhazy, Peter
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Schools of Medicine
Ann Arbor
United States
Zip Code
Matsumoto, Camila S; Almeida, Luciana O; Guimarães, Douglas M et al. (2016) PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells. Oncotarget 7:42393-42407
Pearson, Alexander T; Finkel, Kelsey A; Warner, Kristy A et al. (2016) Patient-derived xenograft (PDX) tumors increase growth rate with time. Oncotarget 7:7993-8005
Arthur, Anna E; Bellile, Emily L; Rozek, Laura S et al. (2016) Pretreatment serum xanthophyll concentrations as predictors of head and neck cancer recurrence and survival. Head Neck 38 Suppl 1:E1591-7
Walline, Heather M; Komarck, Christine M; McHugh, Jonathan B et al. (2016) Genomic Integration of High-Risk HPV Alters Gene Expression in Oropharyngeal Squamous Cell Carcinoma. Mol Cancer Res 14:941-952
Walline, Heather M; Carey, Thomas E; Goudsmit, Christine M et al. (2016) High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res :
Choi, Seung Hee; Terrell, Jeffrey E; Bradford, Carol R et al. (2016) Does Quitting Smoking Make a Difference Among Newly Diagnosed Head and Neck Cancer Patients? Nicotine Tob Res :
Zhang, Yanxiao; Koneva, Lada A; Virani, Shama et al. (2016) Subtypes of HPV-Positive Head and Neck Cancers Are Associated with HPV Characteristics, Copy Number Alterations, PIK3CA Mutation, and Pathway Signatures. Clin Cancer Res 22:4735-45
Rudy, Shannon F; Brenner, J Chad; Harris, Jennifer L et al. (2016) In vivo Wnt pathway inhibition of human squamous cell carcinoma growth and metastasis in the chick chorioallantoic model. J Otolaryngol Head Neck Surg 45:26
Swiecicki, Paul L; Bellile, Emily; Sacco, Assuntina G et al. (2016) A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Invest New Drugs 34:481-9
Prince, Victoria; Bellile, Emily L; Sun, Yilun et al. (2016) Individualized risk prediction of outcomes for oral cavity cancer patients. Oral Oncol 63:66-73

Showing the most recent 10 out of 233 publications